VIVUS (VVUS) Confirms FDA Panel Recommends Approval of Qnexa for Obesity
Up)
VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults. The Committee voted 20 to 2, on the recommendation for an approval based on a favorable benefit-risk profile.
“We are pleased with the panel’s approval recommendation in support of the safety and efficacy of Qnexa,” said Peter Tam, President of VIVUS. “We look forward to working with the FDA as they complete their evaluation. Obesity is a serious medical condition, and we are committed to making Qnexa available and providing physicians with a new medical treatment option in their battle with this public health epidemic.”
The FDA is not bound by the recommendations of its advisory committees, but will consider the guidance during the review of the New Drug Application (NDA) that was submitted for Qnexa in October 2011. The scheduled Prescription Drug User Fee Act (PDUFA) date for Qnexa is April 17, 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
“We are pleased with the panel’s approval recommendation in support of the safety and efficacy of Qnexa,” said Peter Tam, President of VIVUS. “We look forward to working with the FDA as they complete their evaluation. Obesity is a serious medical condition, and we are committed to making Qnexa available and providing physicians with a new medical treatment option in their battle with this public health epidemic.”
The FDA is not bound by the recommendations of its advisory committees, but will consider the guidance during the review of the New Drug Application (NDA) that was submitted for Qnexa in October 2011. The scheduled Prescription Drug User Fee Act (PDUFA) date for Qnexa is April 17, 2012.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Apple's (AAPL) New iPad Shows Rapid Adoption in U.S.
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
